Idarucizumab, marketed as Praxbind, is an antibody that chemically binds and neutralizes the blood-thinning effects of dabigatran. Now, a presentation at the International Stroke Conference 2016 in Los Angeles reports that a newly approved medication reverses the blood-thinning effects of dabigatran in patients suffering an intracranial hemorrhage, potentially limiting the extent of bleeding. Chicago-Brain bleed is among the greatest concerns with novel oral anticoagulants (NOACs), such as dabigatran.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |